Abstract
Either diagnostic delay or tumour biology are possible factors governing the degree of spread at diagnosis of cervical cancer. To try to identify the most important parameter contributing to advanced stage, the duration of symptoms were recorded from patients scheduled for radiotherapy (n = 141) or radical hysterectomy (n = 36). In 146 cases tumour proliferation rates were evaluated following in vivo labelling with the DNA precursor BrdUrd. For symptomatic patients there was no association between duration of symptoms and stage at presentation. There was a significant trend for patients with increasing tumour stage to have more rapidly proliferating tumours with higher mean labelling index (LI) measurements (P = 0.001) and a shorter mean potential doubling time (Tpot) (P = 0.023). Socio economic deprivation may be associated with shorter Tpot values. The conclusion from this data is that stage at diagnosis is more dependent on the biological behaviour of the tumour, as expressed by proliferation rates, than delay in presentation. © 2000 Cancer Research Campaign
Keywords: cervical cancer, diagnosis, proliferation rates
Full Text
The Full Text of this article is available as a PDF (46.4 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bolger B. S., Cooke T. G., Symonds R. P., MacLean A. B., Stanton P. D. Measurement of cell kinetics in cervical tumours using bromodeoxyuridine. Br J Cancer. 1993 Jul;68(1):166–171. doi: 10.1038/bjc.1993.307. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bolger B. S., Symonds R. P., Stanton P. D., MacLean A. B., Burnett R., Kelly P., Cooke T. G. Prediction of radiotherapy response of cervical carcinoma through measurement of proliferation rate. Br J Cancer. 1996 Oct;74(8):1223–1226. doi: 10.1038/bjc.1996.520. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dhooge I. J., Albers F. W., van Cauwenberge P. B. Clinical characteristics and diagnostic delay of head and neck cancer: results from a prospective study in Belgium. Eur J Surg Oncol. 1996 Aug;22(4):354–358. doi: 10.1016/s0748-7983(96)90220-6. [DOI] [PubMed] [Google Scholar]
- Eckert R. L., Agarwal C., Hembree J. R., Choo C. K., Sizemore N., Andreatta-van Leyen S., Rorke E. A. Human cervical cancer. Retinoids, interferon and human papillomavirus. Adv Exp Med Biol. 1995;375:31–44. [PubMed] [Google Scholar]
- Lamont D. W., Symonds R. P., Brodie M. M., Nwabineli N. J., Gillis C. R. Age, socio-economic status and survival from cancer of cervix in the West of Scotland 1980-87. Br J Cancer. 1993 Feb;67(2):351–357. doi: 10.1038/bjc.1993.64. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lombard I., Vincent-Salomon A., Validire P., Zafrani B., de la Rochefordière A., Clough K., Favre M., Pouillart P., Sastre-Garau X. Human papillomavirus genotype as a major determinant of the course of cervical cancer. J Clin Oncol. 1998 Aug;16(8):2613–2619. doi: 10.1200/JCO.1998.16.8.2613. [DOI] [PubMed] [Google Scholar]
- Obermair A., Hanzal E., Schreiner-Frech I., Buxbaum P., Bancher-Todesca D., Thoma M., Kurz C., Vavra N., Gitsch G., Sevelda P. Influence of delayed diagnosis on established prognostic factors in endometrial cancer. Anticancer Res. 1996 Mar-Apr;16(2):947–949. [PubMed] [Google Scholar]
- Palan P. R., Chang C. J., Mikhail M. S., Ho G. Y., Basu J., Romney S. L. Plasma concentrations of micronutrients during a nine-month clinical trial of beta-carotene in women with precursor cervical cancer lesions. Nutr Cancer. 1998;30(1):46–52. doi: 10.1080/01635589809514639. [DOI] [PubMed] [Google Scholar]
- Serur E., Fruchter R. G., Maiman M., McGuire J., Arrastia C. D., Gibbon D. Age, substance abuse, and survival of patients with cervical carcinoma. Cancer. 1995 May 15;75(10):2530–2538. doi: 10.1002/1097-0142(19950515)75:10<2530::aid-cncr2820751020>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
- Tsang R. W., Wong C. S., Fyles A. W., Levin W., Manchul L. A., Milosevic M., Chapman W., Li Y. Q., Pintilie M. Tumour proliferation and apoptosis in human uterine cervix carcinoma II: correlations with clinical outcome. Radiother Oncol. 1999 Jan;50(1):93–101. doi: 10.1016/s0167-8140(98)00119-4. [DOI] [PubMed] [Google Scholar]
- Wilson G. D., Dische S., Saunders M. I. Studies with bromodeoxyuridine in head and neck cancer and accelerated radiotherapy. Radiother Oncol. 1995 Sep;36(3):189–197. doi: 10.1016/0167-8140(95)01567-z. [DOI] [PubMed] [Google Scholar]